Loading
A phase 3 trial of Serplulimab, Carboplatin in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05353257 by Shanghai Henlius Biotech, with 511 participants enrolled, started 2022-05-17 and due to reach its primary completion in 2026-06-30. Interventions recorded: HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI). Conditions listed: Limited-Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Carboplatin, Immune checkpoint inhibitors.